# Vraylar (cariprazine hydrochloride) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/cariprazine

> The next catalyst for Vraylar (cariprazine hydrochloride), sponsored by AbbVie Inc. (ABBV), is its primary completion, March 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Vraylar (cariprazine hydrochloride) |
| Codes |  |
| Sponsor | AbbVie Inc. (ABBV) https://sec-api.dev/companies/abbv/catalysts |
| Indications | Depression |
| Modality |  |
| FDA designations | priority review |

## Timeline

### December 16, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA204370 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20221216, review_priority STANDARD; sponsor_name ABBVIE; product VRAYLAR (CARIPRAZINE HYDROCHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA204370%22

### December 18, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA204370 SUPPL-17 (Efficacy): submission_status AP, submission_status_date 20251218, review_priority PRIORITY; sponsor_name ABBVIE; product VRAYLAR (CARIPRAZINE HYDROCHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA204370%22
- openFDA Drugs@FDA: "NDA204370 SUPPL-15 (Efficacy): submission_status AP, submission_status_date 20251218, review_priority PRIORITY; sponsor_name ABBVIE; product VRAYLAR (CARIPRAZINE HYDROCHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA204370%22
- openFDA Drugs@FDA: "NDA204370 SUPPL-16 (Efficacy): submission_status AP, submission_status_date 20251218, review_priority PRIORITY; sponsor_name ABBVIE; product VRAYLAR (CARIPRAZINE HYDROCHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA204370%22
- openFDA Drugs@FDA: "NDA204370 SUPPL-14 (Efficacy): submission_status AP, submission_status_date 20251218, review_priority STANDARD; sponsor_name ABBVIE; product VRAYLAR (CARIPRAZINE HYDROCHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA204370%22

### March 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Depression; Bipolar I Disorder.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04777357 (A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT04777357

### Mar to Jun 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Depression; Bipolar I Disorder.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04777357 (A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT04777357

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/cariprazine.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Vraylar (cariprazine hydrochloride) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/cariprazine

```bibtex
@misc{secapidev_pdufa_cariprazine_20261116,
  title        = {Vraylar (cariprazine hydrochloride) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/cariprazine}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_cariprazine_20261116","title":"Vraylar (cariprazine hydrochloride) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/cariprazine","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
